394 related articles for article (PubMed ID: 18980985)
1. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
2. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
Chow KU; Boehrer S; Geduldig K; Krapohl A; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2001 May; 86(5):485-93. PubMed ID: 11410411
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
4. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
Glode AE; Jarkowski A
Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
[TBL] [Abstract][Full Text] [Related]
9. BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32).
De Angeli C; Gandini D; Cuneo A; Moretti S; Bigoni R; Roberti MG; Bardi A; Castoldi GL; del Senno L
Haematologica; 2000 Sep; 85(9):913-21. PubMed ID: 10980628
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
11. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
Duechler M; Linke A; Cebula B; Shehata M; Schwarzmeier JD; Robak T; Smolewski P
Eur J Haematol; 2005 May; 74(5):407-17. PubMed ID: 15813915
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia.
Schwänen C; Hecker T; Hübinger G; Wölfle M; Rittgen W; Bergmann L; Karakas T
Leukemia; 2002 Oct; 16(10):2096-105. PubMed ID: 12357363
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine: a new look at an old drug.
Kalaycio M
Cancer; 2009 Feb; 115(3):473-9. PubMed ID: 19117340
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine: rebirth of an old drug.
Cheson BD; Rummel MJ
J Clin Oncol; 2009 Mar; 27(9):1492-501. PubMed ID: 19224851
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine in the treatment of chronic lymphocytic leukemia.
Knauf W
Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
[TBL] [Abstract][Full Text] [Related]
18. Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
Ferrer A; Marcé S; Bellosillo B; Villamor N; Bosch F; López-Guillermo A; Espinet B; Solé F; Montserrat E; Campo E; Colomer D
Oncogene; 2004 Nov; 23(55):8941-9. PubMed ID: 15480431
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines.
Konstantinov SM; Kostovski A; Topashka-Ancheva M; Genova M; Berger MR
J Cancer Res Clin Oncol; 2002 May; 128(5):271-8. PubMed ID: 12029443
[TBL] [Abstract][Full Text] [Related]
20. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]